Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones
This pooled analysis (s=9) examined how much session facilitators shape participants' acute subjective effects across psilocybin studies involving 298 participants and 60 facilitators, finding that facilitator influence was negligible in healthy volunteers (0.8% of variance) but clinically meaningful in patient samples (13.6%), comparable to or exceeding typical therapist effects seen in conventional psychotherapy.
Authors
- Albert Garcia-Romeu
- Natalie Gukasyan
- Frederick Barrett
Published
Abstract
Psychedelics' characteristic acute subjective effects predict therapeutic benefits, such as decreases in depression and anxiety. Thus, optimizing treatment involves better understanding which factors shape subjective effects. Session facilitators, who support participants before, during, and after psychedelic administration sessions, form an important part of the setting of these experiences. Yet, the extent to which session facilitators influence participants' acute subjective effects is unknown. To address this gap, we analyzed data from 9 psilocybin administration studies involving 298 participants, 670 dosing sessions, and 60 facilitators-the largest dataset of its kind. Using multilevel models, we examined whether facilitators contributed to variance in participants' acute subjective effects. Results showed that facilitators accounted for negligible variance (0.8 %) in healthy volunteers, but greater variance in clinical samples (13.6 %), after controlling for study and participant differences. These findings reveal that facilitators may play a clinically meaningful role in shaping psychedelic treatment outcomes in patient populations, relative to non-patients, comparable to or exceeding therapist effects in traditional psychotherapy (∼8 %). These results have direct implications for clinical trial design, training protocols, and the implementation of psychedelic treatments as they continue to scale.
Research Summary of 'Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones'
Blossom's Take
Does it matter who is facilitating a psychedelic-assisted therapy session (and more specifically, for psilocybin)? This cross-study analysis argues that it matters very little for healthy subject studies, but it accounted for nearly 14% of the variance in clinical populations. This effect is larger than in 'traditional' psychotherapy (8%).
Introduction
Classic psychedelics are being studied as treatments for a range of disorders, and their therapeutic effects appear to depend partly on the quality of the acute subjective experience. The paper notes that mystical-type experience, often measured with the Mystical Experience Questionnaire (MEQ), has been linked in earlier research to improvements in depression, anxiety, life satisfaction, and substance use. At the same time, psychedelic sessions are usually supported by two facilitators, yet it has been unclear whether individual facilitators meaningfully shape participants’ experiences. The authors frame this as an important gap because, if facilitators influence subjective effects, this would affect how psychedelic therapy should be understood and standardised. P. and colleagues set out to examine whether session facilitators account for variation in acute subjective effects during psilocybin administration sessions, and whether this differs between clinical populations and healthy volunteers. They present what they describe as the largest and most comprehensive analysis to date of facilitator influence on psilocybin experiences, using pooled trial data from the Johns Hopkins Centre for Psychedelic and Consciousness Research. The aim was to quantify how much of the variation in MEQ scores could be attributed to facilitators after accounting for participant, dose, and study-level differences.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typemeta
- Journal
- Compound
- Topics
- Authors
- APA Citation
Goldy, S. P., Sepeda, N. D., Hilbert, S. N., Bari, B. A., Garcia-Romeu, A., Gukasyan, N., Barrett, F. S., Yaden, D. B., & Nayak, S. M. (2026). Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones. Psychiatry Research, 359, 117010. https://doi.org/10.1016/j.psychres.2026.117010
References (47)
Papers cited by this study that are also in Blossom
Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)
Barrett, F. S., Doss, M. K., Sepeda, N. D. et al. · Scientific Reports (2020)
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)
Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)
Carbonaro, T. M., Hurwitz, E., Johnson, M. W. · Psychopharmacology (2017)
Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)
Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)
D’Souza, D. C., Syed, S. A., Safi-Aghdam, H. et al. · Neuropsychopharmacology (2022)
Davis, A. K., Clifton, J. M., Weaver, E. G. et al. · Journal of Psychopharmacology (2020)
Davis, A. K., Streeter Barrett, F., Griffiths, R. R. et al. · Journal of Psychopharmacology (2021)
Show all 47 referencesShow fewer
Garcia-Romeu, A., Griffiths, R. R., Johnson, M. W. · Current Drug Abuse Reviews (2015)
Goodwin, G. M., Aaronson, S. T., Alvarez, O. et al. · New England Journal of Medicine (2022)
Goodwin, G. M., Malievskaia, E., Fonzo, G. A. et al. · American Journal of Psychiatry (2023)
Goodwin, G. M., Aaronson, S. T., Alvarez, O. et al. · Journal of Affective Disorders (2025)
Gründer, G., Brand, M., Mertens, L. J. et al. · Lancet Psychiatry (2024)
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
Griffiths, R. R. · Journal of Psychopharmacology (2008)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Journal of Psychopharmacology (2017)
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Hinkle, J. T., Graziosi, M., Nayak, S. et al. · JAMA Psychiatry (2024)
Holze, F., Ley, L., Müller, F. et al. · Neuropsychopharmacology (2022)
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)
Johnson, M. W., Garcia-Romeu, A., Griffiths, R. R. · The American Journal of Drug and Alcohol Abuse (2016)
Lawrence, D. W., Carhart-Harris, R. L., Griffiths, R. R. et al. · Research Square (2022)
Levin, A. W., Lancelotta, R., Sepeda, N. D. et al. · PLOS ONE (2024)
Ley, L., Holze, F., Arikci, D. et al. · Neuropsychopharmacology (2023)
Ludwig, A., Levine, J., Stark, L. et al. · American Journal of Psychiatry (1969)
MacLean, K. A., Leoutsakos, J. S., Johnson, M. W. et al. · Journal for the Scientific Study of Religion (2012)
Murphy, R., Murphy-Beiner, A., Kettner, H. et al. · Frontiers in Pharmacology (2022)
Nayak, S., Johnson, M. W. · Pharmacopsychiatry (2020)
Olson, D. E. · ACS Pharmacology and Translational Science (2020)
Raison, C. L., Sanacora, G., Woolley, J. D. et al. · JAMA (2023)
Reckweg, J., van Leeuwen, C., Theunissen, E. L. et al. · Frontiers in Psychiatry (2023)
Rieser, N. M., Bitar, R., Halm, S. et al. · EClinicalMedicine (2025)
Roseman, L., Demetriou, L., Wall, M. B. et al. · Neuropharmacology (2018)
Roseman, L., Nutt, D. J., Carhart-Harris, R. L. · Frontiers in Pharmacology (2018)
Roseman, L., Haijen, E. C. H. M., Idialu-Ikato, K. et al. · Journal of Psychopharmacology (2019)
Ross, S., Bossis, A. P., Guss, J. et al. · Journal of Psychopharmacology (2016)
Schindowski, E. M., Jungwirth, J., Schuldt, A. et al. · EClinicalMedicine (2023)
Simonsson, O., Hendricks, P. S., Chambers, R. et al. · Journal of Affective Disorders (2023)
Timmermann, C., Roseman, L., Schartner, M. et al. · Scientific Reports (2019)
Wardle, M. C., De Wit, H. · Psychopharmacology (2014)
Watts, R., Kettner, H., Gandy, S. et al. · Psychopharmacology (2022)
Weiss, B., Leor Roseman, •., Giribaldi, B. et al. · International Journal of Mental Health and Addiction (2024)
Yaden, D. B., Griffiths, R. R. · ACS Pharmacology and Translational Science (2020)
Yaden, D. B., Goldy, S. P., Weiss, B. et al. · Nature Reviews Psychology (2024)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.